Biodel Inc. (BIOD.O)
3.79USD
11 Dec 2009
$0.07 (+1.88%)
$3.72
$3.74
$3.91
$3.66
25,457
47,034
$6.02
$2.19
BIOD.O
About
Overall
| Beta: | 0.80 |
| Market Cap (Mil.): | $88.54 |
| Shares Outstanding (Mil.): | 23.80 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| BIOD.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.55 | 4.61 |
| EPS (TTM): | -3.70 | -- | -- |
| ROI: | -56.65 | 1.82 | 2.82 |
| ROE: | -56.67 | 2.44 | 4.12 |
Biodel shares dive as diabetes study disappoints
LONDON (Reuters) - Shares of Biodel Inc plunged nearly 70 percent on Monday after a late-stage clinical trial cast doubt on its experimental diabetes drug VIAject.
Biodel shares dive as diabetes study disappoints
LONDON (Reuters) - Biodel shares plunged nearly 70 percent on Monday after a Phase III clinical trial cast doubt about its diabetes drug VIAject.
Biodel's diabetes drug VIAject meets goals
LONDON, Sept 8 (Reuters) - Two studies have shown Biodel Inc's diabetes drug VIAject is as effective as Eli Lilly and Co's Humulin at controlling blood sugar level in people with diabetes, the company said on Monday.
UPDATE 1-RESEARCH ALERT-JPMorgan starts Biodel with overweight
Feb 27 (Reuters) - J.P. Morgan Securities started Biodel Corp with an "overweight" rating stating it had a high degree of confidence in a favorable Phase III outcome of the company's insulin product.
Biodel files to offer 3.8 mln shares
Jan 16 (Reuters) - Biodel Inc said in a filing with the U.S. Securities and Exchange Commision that 3.8 million shares of its common stock is being offered for sale.
Biodel says CFO to leave, replacement named
Nov 14 (Reuters) - Specialty pharmaceutical company Biodel Inc said Chief Financial Officer Scott Reding was resigning to pursue other interests and would be replaced by Gerard Michel, effective Nov. 20.
Biodel says amendment to widen Q3 net loss
Sept 19 (Reuters) - Biodel Inc said it will file an amended quarterly report to record an additional non-cash stock-based compensation expense, widening its third-quarter net loss by 9 cents a share.
Biodel 3rd-qtr net loss widens
July 30 (Reuters) - Specialty pharmaceutical company Biodel Inc. posted a wider third-quarter net loss. The company said it reported third-quarter net loss of $3.7 million, or 21 cents a share, compared with a loss of $2.3 million, or 31 cents per share, in the year-ago period.
UPDATE 1-RESEARCH ALERT-BofA starts Biodel with buy, targets $23
June 20 (Reuters) - Banc of America Securities began coverage of speciality pharmaceutical company Biodel Inc. with a "buy" rating and $23 price target.
Competitors
| Price | Change | |
|---|---|---|
| Eli Lilly & Co. (LLY.N) | $34.97 | -0.05 |
| Novo Nordisk A/S (NOVOb.CO) | kr.336.00 | -4.00 |
| Sanofi-Aventis SA (SASY.PA) | €52.70 | -0.20 |
| Halozyme Therapeutics, Inc. (HALO.OQ) | $6.05 | +0.10 |
| Generex Biotechnology Corporation (GNBT.OQ) | $0.56 | -0.00 |
| MannKind Corporation (MNKD.OQ) | $8.20 | +0.40 |
| Merck & Co., Inc. (MRK.N) | $37.07 | -0.09 |
| Procter & Gamble Hygiene & Health Care (PROC.BO) | Rs1,760.30 | +17.25 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
